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Abstracts
 
product, presenting it objectively, without exaggeration
and without being misleading. EFPIA and IFPMA also
publish Codes of Practice for the Promotion of Medi-
cines. In these approaches HE data are not explicitly con-
sidered; the focus is clinical. Similarly, until recently, leg-
islation for the separate review of HE data did not exist
in the US. In addition, a recent cross-functional initiative
through ISPOR to develop guidelines for healthcare eco-
nomic promotional materials has now been reported.
CONCLUSION: We have identified no specific guide-
lines for advertising using HE data in the EU. Given this,
key questions are: 1) Do existing codes of practice offer
enough scope to review HE data? and 2) How can we en-
sure quality assurance of HE information provided to de-
cision-makers?
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Quality of life and patient satisfaction cohabit more and
more in the same paradigm, through the notion that pa-
tient satisfaction with care and treatment can lead to pos-
itive outcomes, which in turn adds to overall clinical ef-
fectiveness. Yet patient satisfaction is often used without
a clear understanding of the concept.
OBJECTIVE: To test a model of patient satisfaction that
would identify the antecedents of the satisfaction judgment.
METHOD: Self-administered questionnaire to 532 inpa-
tients of two acute-care hospitals in Montreal (Canada).
The questionnaire consisted of six Likert scales measur-
ing: expectations (3 items), perceived quality (17 items),
conformity to expectations (3 items), needs (6 items),
fairness (2 items), and satisfaction (10 items). Scales reli-
ability and construct validity were assessed with Cron-
bach alpha coefficient of internal consistency and confir-
matory factorial analysis. The model was tested with
causal modeling (LISREL 8).
RESULTS: All alpha coefficients ranged from 0.70 to
0.91. The model provides satisfactory fit to the data (
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26.44, df 
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 28, p 
 

 
 0.55) and explains 61% of the varia-
tion in satisfaction. Examination of total effects (sum of di-
rect and indirect effects of one variable on another) reveals
that perceived quality has the greatest influence on satis-
faction (total effect 0.62), followed by conformity to ex-
pectation (total effect 0.44), fairness (total effect 0.44),
needs (total effect 0.16), and expectations (total effect
0.11). In conclusion, the utilization of satisfaction informa-
tion to its full potential not only requires reliable and valid
instruments, but also relevant concepts, such as perceived
quality and conformity to expectations, to take into ac-
count the complexity of the satisfaction judgment.
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Farmaci, Azienda Ospedaliera Careggi, Florence, Italy
OBJECTIVES: The analysis of published survival curves
can be used as the basis for conducting cost-effectiveness
analyses in which two treatments are compared in terms
of cost per life year saved. In patients with metastatic
breast cancer, high-dose chemotherapy (HDC) with au-
tologous bone marrow transplantation (ABMT) has been
reported to improve survival in comparison with control
patients who receive standard chemotherapy.
METHODS: An incremental cost-effectiveness analysis
was undertaken in which the Gompertz model was used
to determine a lifetime estimate of patient-years gained
by subjects given HDC with hematopoietic rescue in
comparison with controls. Our study utilized the clinical
data reported in a published clinical trial. This random-
ized clinical trial involved 45 patients subjected to HDC
with ABMT and 45 controls given chemotherapy.
RESULTS: Lifetime survival advantage for patients in the
HDC with ABMT group was estimated as 72.5 discounted
patient-years for every 100 patients. The use of HDC with
ABMT, as opposed to standard chemotherapy alone, was
associated with an incremental cost of about $55,000 per
discounted life year gained.
CONCLUSIONS: The cost-effectiveness ratio of high-
dose chemotherapy combined with autologous bone mar-
row transplantation in patients with metastatic breast can-
cer is borderline if one considers that acceptable figures of
cost per life year gained are generally below $50,000.
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We describe a new method for expressing survival in can-
cer. Our method has the following characteristics: In ana-
lyzing a survival curve (first analysis), the plateau of the
right portion of the curve is extrapolated to infinity by as-
signing a normal life expectancy to long-term survivors
(“cured” patients). A second survival curve (second anal-
ysis), which represents the expected survival of a healthy
patient cohort (age-matched and gender-matched with
the patient cohort under study), is constructed. The sec-
ond curve is used as a reference for internal compari-
sons. Both curves are assessed by measuring the area un-
der the curve (AUC). The ratio of the AUC from the first
analysis to the AUC from the second analysis quantifies
